Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01340196 · ClinicalTrials.gov registry record · Phase 1
Drug Drug Interaction of BI 201335 and Tenofovir
A Phase 1 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT01340196 is a Phase 1 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 16 participants.
The verdict
NCT01340196, a Phase 1 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the drug-drug interaction potential between BI 201335 and concomitantly administered tenofovir which is used in treatment regimens for HIV infection and/or Hepatitis B infection. Results of this study will serve as a basis for guidance of dose adjustments or other precautionary measures when BI201335 and tenofovir are coadministered.
Interventions
- DRUG tenofovir/BI 201335
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2011-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01340196
The ClinicalTrials.gov registry entry for NCT01340196 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which tenofovir/BI 201335 is the first listed.
NCT01340196 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01340196 about?
NCT01340196 is a clinical study titled "Drug Drug Interaction of BI 201335 and Tenofovir". The objective of this study is to evaluate the drug-drug interaction potential between BI 201335 and concomitantly administered tenofovir which is used in treatment regimens for HIV infection and/or Hepatitis B infection. Results of this study will serve as a basis for guidance of dose adjustments o...
What is the current status of trial NCT01340196?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2011-04.
What interventions are being tested in trial NCT01340196?
The interventions under investigation include: tenofovir/BI 201335 (DRUG).
Who is sponsoring clinical trial NCT01340196?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.